Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Standard
Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis : A retrospective multicenter study. / Schwensen, J F; Clemmensen, A; Sand, C; Gniadecki, R; Skov, L; Zachariae, C; Iversen, L; Rasmussen, M; Thomsen, S F.
I: Dermatologic Therapy, Bind 30, Nr. 6, e12550, 11.2017.Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis
T2 - A retrospective multicenter study
AU - Schwensen, J F
AU - Clemmensen, A
AU - Sand, C
AU - Gniadecki, R
AU - Skov, L
AU - Zachariae, C
AU - Iversen, L
AU - Rasmussen, M
AU - Thomsen, S F
N1 - © 2017 Wiley Periodicals, Inc.
PY - 2017/11
Y1 - 2017/11
N2 - Secukinumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety lack. We aimed to present real-life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off-label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)-50 and PASI-75 of 66.7% and 52.9%, respectively. A total of 83.0% (44/53) and 60.4% (32/53) of the patients had a PASI-score < 5 and PASI-score < 2, respectively, after 12 weeks on treatment with secukinumab. A third of the patients had secukinumab discontinued due to limited clinical improvement or adverse events (n = 23) within a median of 92 days (interquartile range 51-212 days). Notably, the majority of the patients may represent a particularly difficult-to-treat group of patients, as 92.8% had been refractory to other biologic treatment. A total of 26.1% (n = 18) experienced adverse events. Secukinumab appears to be an effective treatment option with a favorable side effect profile in patients with plaque psoriasis who are refractory to or have side effects of traditional biologic drugs.
AB - Secukinumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety lack. We aimed to present real-life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off-label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)-50 and PASI-75 of 66.7% and 52.9%, respectively. A total of 83.0% (44/53) and 60.4% (32/53) of the patients had a PASI-score < 5 and PASI-score < 2, respectively, after 12 weeks on treatment with secukinumab. A third of the patients had secukinumab discontinued due to limited clinical improvement or adverse events (n = 23) within a median of 92 days (interquartile range 51-212 days). Notably, the majority of the patients may represent a particularly difficult-to-treat group of patients, as 92.8% had been refractory to other biologic treatment. A total of 26.1% (n = 18) experienced adverse events. Secukinumab appears to be an effective treatment option with a favorable side effect profile in patients with plaque psoriasis who are refractory to or have side effects of traditional biologic drugs.
KW - Journal Article
U2 - 10.1111/dth.12550
DO - 10.1111/dth.12550
M3 - Letter
C2 - 28906051
VL - 30
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
IS - 6
M1 - e12550
ER -
ID: 183469566